We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?
Read MoreHide Full Article
Key Takeaways
MED emphasizes metabolic health as GLP-1 drugs reshape weight-loss and wellness trends.
Clinical results show 98% lean mass retention and 14% visceral fat reduction in 16-week programs.
Digital tools, Premier plus pricing and EDGE coaching aim to boost retention and support 2026 growth.
Medifast, Inc. (MED - Free Report) recognizes that the weight-loss and wellness landscape has evolved quickly as GLP-1 drugs gain wider adoption, reshaping how obesity and health are viewed by offering an effective way to suppress appetite and lose weight. While powerful, GLP-1 therapies are not enough for long-term health, as most weight-related challenges come from poor metabolic health that medication alone cannot fix.
Studies show that up to 40% of weight lost on GLP-1 medications comes from muscle, while nearly 74% of users stop treatment within a year, often regaining much of the weight. This creates a real opportunity for Medifast to help restore natural metabolic function. With more than 90% of U.S. adults being unhealthy metabolically, the company addresses a major public health challenge and a rare chance to redefine long-term wellness.
Medifast is positioning itself as a leader in metabolic health, with its growth strategy focused on “metabolic synchronization,” an approach aimed at reversing metabolic dysfunction. Clinical results show targeted fat loss with better body composition: at 16 weeks, participants kept 98% of lean mass, cut visceral fat by 14%, and preserved muscle while improving metabolic health. The program supports clients using GLP-1s, transitioning off them, or not using them, offering a complete, long-term foundation for healthier living.
The company also continues to invest in its digital platforms, improving its app and reporting tools to better track client progress and coach performance. Along with simplified Premier+ pricing and the EDGE leadership program, these efforts help boost retention, increase productivity and strengthen coach stability, with early signs of sustained success heading into 2026.
Medifast’s focus on metabolic health, digital enablement and coach-led support positions it to complement or extend beyond GLP-1 use, creating a differentiated, sustainable growth path despite evolving weight-loss dynamics.
Zacks Rundown for MED
Medifast’s shares have lost 14.1% in the past six months compared with the industry’s decline of 9.8%. MED currently carries a Zacks Rank #4 (Sell).
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.38, lower than the industry’s average of 1.06.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current and next fiscal-year earnings implies year-over-year declines of 158.7% and 5.6%, respectively.
Image Source: Zacks Investment Research
Better-Ranked Stocks to Consider
The Vita Coco Company, Inc. (COCO - Free Report) develops, markets and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa and the Asia Pacific. COCO currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco's current fiscal-year sales and earnings implies growth of 18% and 15%, respectively, from the year-ago reported figures. Vita Coco delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Monster Beverage Corporation (MNST - Free Report) engages in the development, marketing, sale and distribution of energy drink beverages and concentrates in the United States and internationally. MNST currently sports a Zacks Rank #1.
The Zacks Consensus Estimate for Monster Beverage's current fiscal-year sales and earnings implies growth of 9.6% and 22.2%, respectively, from the year-ago actuals. MNST delivered a trailing four-quarter earnings surprise of 5.5%, on average.
United Natural Foods, Inc. (UNFI - Free Report) distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural carries a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for United Natural’s current fiscal-year sales and earnings implies growth of 1% and 187.3%, respectively, from the year-ago reported figures. UNFI delivered a trailing four-quarter earnings surprise of 52.1%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?
Key Takeaways
Medifast, Inc. (MED - Free Report) recognizes that the weight-loss and wellness landscape has evolved quickly as GLP-1 drugs gain wider adoption, reshaping how obesity and health are viewed by offering an effective way to suppress appetite and lose weight. While powerful, GLP-1 therapies are not enough for long-term health, as most weight-related challenges come from poor metabolic health that medication alone cannot fix.
Studies show that up to 40% of weight lost on GLP-1 medications comes from muscle, while nearly 74% of users stop treatment within a year, often regaining much of the weight. This creates a real opportunity for Medifast to help restore natural metabolic function. With more than 90% of U.S. adults being unhealthy metabolically, the company addresses a major public health challenge and a rare chance to redefine long-term wellness.
Medifast is positioning itself as a leader in metabolic health, with its growth strategy focused on “metabolic synchronization,” an approach aimed at reversing metabolic dysfunction. Clinical results show targeted fat loss with better body composition: at 16 weeks, participants kept 98% of lean mass, cut visceral fat by 14%, and preserved muscle while improving metabolic health. The program supports clients using GLP-1s, transitioning off them, or not using them, offering a complete, long-term foundation for healthier living.
The company also continues to invest in its digital platforms, improving its app and reporting tools to better track client progress and coach performance. Along with simplified Premier+ pricing and the EDGE leadership program, these efforts help boost retention, increase productivity and strengthen coach stability, with early signs of sustained success heading into 2026.
Medifast’s focus on metabolic health, digital enablement and coach-led support positions it to complement or extend beyond GLP-1 use, creating a differentiated, sustainable growth path despite evolving weight-loss dynamics.
Zacks Rundown for MED
Medifast’s shares have lost 14.1% in the past six months compared with the industry’s decline of 9.8%. MED currently carries a Zacks Rank #4 (Sell).
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.38, lower than the industry’s average of 1.06.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current and next fiscal-year earnings implies year-over-year declines of 158.7% and 5.6%, respectively.
Image Source: Zacks Investment Research
Better-Ranked Stocks to Consider
The Vita Coco Company, Inc. (COCO - Free Report) develops, markets and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa and the Asia Pacific. COCO currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco's current fiscal-year sales and earnings implies growth of 18% and 15%, respectively, from the year-ago reported figures. Vita Coco delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Monster Beverage Corporation (MNST - Free Report) engages in the development, marketing, sale and distribution of energy drink beverages and concentrates in the United States and internationally. MNST currently sports a Zacks Rank #1.
The Zacks Consensus Estimate for Monster Beverage's current fiscal-year sales and earnings implies growth of 9.6% and 22.2%, respectively, from the year-ago actuals. MNST delivered a trailing four-quarter earnings surprise of 5.5%, on average.
United Natural Foods, Inc. (UNFI - Free Report) distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural carries a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for United Natural’s current fiscal-year sales and earnings implies growth of 1% and 187.3%, respectively, from the year-ago reported figures. UNFI delivered a trailing four-quarter earnings surprise of 52.1%, on average.